Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice
Bruton tyrosine kinase (BTK) inhibitors represent an important therapeutic advancement for B cell malignancies. Ibrutinib, the first-in-class BTK inhibitor, is approved by the US FDA to treat patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and mantle cell lymphoma...
Enregistré dans:
| Auteurs principaux: | , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Frontiers Media S.A.
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/b1b57d9d157d496799b9fdf515094b55 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|